Fintech PR
Wolters Kluwer Accelerates in Innovative Solutions at the 2019 American Association of Law Libraries Conference
Wolters Kluwer Legal & Regulatory U.S. will showcase a diverse portfolio of new and recently enhanced solutions for legal professionals at the 2019 American Association of Law Libraries (AALL) Annual Meeting and Conference in Washington, DC on July 13-16. Following a wave of new offerings in recent years, the company’s portfolio at this year’s conference further demonstrates its track record of developing innovative solutions driven by direct feedback from customers.
“Wolters Kluwer has been on a path of unprecedented innovation focused on customer-centric development in recent years,” said Dean Sonderegger, the newly appointed Senior Vice President and General Manager of Wolters Kluwer Legal & Regulatory U.S. “That trajectory has prepared us to move faster to develop impactful solutions that integrate cutting edge technology with our historic expertise, and we are looking forward to showcasing our progress at this year’s conference.”
The AALL Annual Meeting and Conference’s theme for the year, “Capitalizing on Our Strengths,” is reflective of the portfolio that Wolters Kluwer will showcase at the conference. With a wide range of solutions on display, the company will highlight new and enhanced offerings that combine best-in-class technology, Wolters Kluwer’s market-leading content, and expert-driven thought leadership.
Expansion of Acclaimed Securities Portfolio
Wolters Kluwer continues to extend its position as a market leader in transactional law support of SEC research, filings preparations, and mergers and acquisitions through ongoing innovation within its Transactional Law Suite for Securities. The suite includes AI-powered M&A Clause Analytics, which improves and streamlines the M&A drafting process; RBsource, RBsourceFilings and RegReview to optimize SEC research; and Clarion, which provides tools to optimize due diligence and client counsel.
Building on this market-staple portfolio, Wolters Kluwer just launched Capital Markets Clause Analytics, a workflow solution that combines the power of artificial intelligence with curation by expert attorneys. This latest addition to the Transactional Law Suite for Securities sets a new standard for transforming the capital markets document drafting workflow for attorneys and securities professionals.
“Our securities solutions, merging best-in-class content and cutting-edge technology, have taken the next leap forward,” said Susan Chazin, Securities & Banking, Product Line Director, Wolters Kluwer Legal & Regulatory U.S. “These solutions were built upon direct feedback from our valued customers, and we are proud that the substantial, meaningful innovation we have driven in this practice area has been very well received by the market.”
Best-in-Class Research Solutions
Wolters Kluwer continues to build upon its reputation for developing best-in-class research solutions that directly support customers’ workflow needs. Earlier this year, the company announced the launch of Tax Essentials, a new digital tax research and analysis solution that streamlines the research process for tax attorneys and legal professionals. With more than 1,000 federal, state and international tax topics developed by industry-leading tax experts, Tax Essentials provides an unprecedented breadth of coverage that combines topical navigation, in-depth content, and innovative tools for a 360-degree view of legal tax topics.
The company also re-launched Kluwer International Tax Law, a state-of-the-art research platform that integrates Wolters Kluwer’s market-leading content with an intuitive user interface and practical tools for legal professionals advising on international tax law matters. Reimagined with international legal tax professionals’ workflow in mind, the enhanced solution has several upgraded features to provide quick, comprehensive access to international tax topics.
AI-Enhanced Tools for a Shifting Regulatory Environment
As legal professionals face the challenges of a rapidly changing regulatory environment, Wolters Kluwer has accelerated the development of solutions that provide practitioners with tools to easily navigate treacherous terrain.
At this year’s conference, Wolters Kluwer will highlight its collaboration with ktMINE, a growing IP data and information services firm, that has bolstered Wolters Kluwer’s market-leading intellectual property and workflow solutions. Available through Wolters Kluwer’s premier research platform Cheetah
, users can access IP content relevant to negotiating royalty rates, licensing agreements, patent, trademark, mergers and acquisitions deal data and detailed agreement summaries from public sources including the Securities and Exchange Commission, foreign security filings and the web.
“Our customers rely on us not only to listen to them and help them solve their pain points, but to also look beyond what they need right now and help them to prepare for the future,” said Sonderegger. “As we continue to develop and enhance our portfolio of solutions, we’re looking forward to our continued collaboration with our customers so that we can deliver best-in-class, expert solutions that deliver actionable insight and deep impact.”
SOURCE Wolters Kluwer Legal & Regulatory U.S.
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Fintech4 days agoHow to identify authenticity in crypto influencer channels
-
Latest News7 days ago
BMO Announces Election of Board of Directors
-
Latest News4 days ago
HSBC-backed fintech Monese is considering splitting its operations as it grapples with increasing losses.
-
Latest News3 days ago
EverBank has announced a groundbreaking partnership with Finzly, poised to revolutionize payment processing.
-
Latest News3 days ago
FinTech leaders express caution regarding the promises made in #Budget2024 concerning open banking, stating that the “devil is in the details.”
-
Latest News3 days ago
Gotion High-tech’s operating profit up 391% in 2023, nearly RMB 2.8 billion invested in R&D for the year
-
Latest News3 days ago
Aurionpro Solutions acquires Arya.ai, to power next generation Enterprise AI platforms for Financial Institutions
-
Latest News4 days ago
Wells Fargo, a leading financial institution, is set to revolutionize its trade finance operations by incorporating artificial intelligence (AI) technology through its collaboration with TradeSun.